Leading medical technology company, Medtronic has revealed that it has received the approval from the Food and Drug Administration (FDA) in the United States for the usage of its new catheter system to treat paroxysmal atrial fibrillation.
The Arctic Front Cardiac CryoAblation Catheter system has already received positive responses from various doctors in the country and is known to successfully treat the common heart rhythm disorder.
This is only the second such catheter system to be approved in the United States and while treating atrial fibrillation through catheter ablation is still in its infancy, leading medical experts predict that the market will see a big growth in the near future.
"The physician community likes cryo. They consider it safe, and so from that perspective I think Medtronic has a good device on the market and will be able to take market share. I think it's a big deal", the analyst for Noble Financial Capital Markets, Jan Wald said.